Dermira Presents Data From DRM01 Phase 2a Trial at European Academy of Dermatology and Venereology
October 07, 2015 at 07:30 AM EDT
Dermira, Inc. (NASDAQ: DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to ...
